Naxicap Partners has acquired Groupe Moria
Naxicap Partners has acquired Groupe Moria from Bridgepoint Development Capital.
Naxicap Partners is a French private equity firm operating in all sectors and focusing on leverage buy-outs and growth capital. For more than 30 years, the firm has invested in ambitious companies in France, Benelux and Spain through controlling majority stakes. As of 31 December 2017, Naxicap Partners manages US$3.5 billion for BPCE Group (33%) and for global institutional investors (67%).
Groupe Moria manufactures and distributes ophthalmic surgery consumables, single use and reusable instruments addressing refractive, corneal, cataract and retinal procedures. The company benefits from strong know-how, combining handcraft capabilities and state-of-the-art technology located in two industrial facilities in France. Present in nearly 80 countries, the group reaches its end customers worldwide through to a tier-2 distribution model (direct sales to surgeons and healthcare facilities and indirect sales via distributors and wholesalers).
Bridgepoint Development Capital is a major international private equity group focused on buy-outs and growth capital investments, typically in businesses with an enterprise value of between US$22–267 million. The firm currently operates in the UK, France and the Nordic region.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Related deals
Valmiermuižas Alus has been acquired by Cēsu Alus
Valmiermuižas Alus has been acquired by Cēsu Alus AS through the purchase of 100% of its shares. The transaction enabled the founder’s exit and strengthened the company’s platform for continued growth within a consolidating Baltic beverage market.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreArmira has signed an agreement to acquire a majority stake in Viabus
Armira, a Germany-based investment firm, has signed an agreement to acquire a majority stake in Viabus, a leading Dutch tour operator focused on senior and young senior travelers.
Learn more